WO2004010993A1 - Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent - Google Patents
Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent Download PDFInfo
- Publication number
- WO2004010993A1 WO2004010993A1 PCT/US2003/022889 US0322889W WO2004010993A1 WO 2004010993 A1 WO2004010993 A1 WO 2004010993A1 US 0322889 W US0322889 W US 0322889W WO 2004010993 A1 WO2004010993 A1 WO 2004010993A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- weight
- comprised
- simvastatin
- dosage unit
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the instant invention involves a pharmaceutical formulation for bulk composition and oral dosage units comprised of the combination of a 3-hydroxy-3- methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, particularly simvastatin, with a cholesterol absorption inhibitor, particularly ezetimibe, or pharmaceutically acceptable salts, solvates or esters of these compounds, which is useful for lipid management and for preventing and treating atherosclerotic diseases and related conditions and disease events.
- HMG-CoA 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitor
- simvastatin a cholesterol absorption inhibitor
- ezetimibe or pharmaceutically acceptable salts, solvates or esters of these compounds
- LDL low density lipoprotein
- HDL high density lipoprotein
- this therapy is not easy to administer or tolerate and was therefore often unsuccessful except in specialist lipid clinics.
- the fibrates produce a moderate reduction in LDL cholesterol accompanied by increased HDL cholesterol and a substantial reduction in triglycerides, and because they are well tolerated these drugs have been more widely used.
- Probucol produces only a small reduction in LDL cholesterol and also reduces HDL cholesterol, which, because of the strong inverse relationship between HDL cholesterol level and CHD risk, is generally considered undesirable.
- lovastatin the first inhibitor of HMG-CoA reductase to become available for prescription in 1987, for the first time physicians were able to obtain large reductions in plasma cholesterol with very few adverse effects.
- cholesteryl ester formation and reduction of serum cholesterol is likely to inhibit the progression of atherosclerotic lesion formation, decrease the accumulation of cholesteryl esters in the arterial wall, and block the intestinal absorption of dietary cholesterol.
- Further risk reduction can be achieved with a combination therapy comprised of an HMG-CoA reductase inhibitor such as simvastatin with a cholesterol absorption inhibitor such as ezetimibe to provide lipid management, and to treat or reduce the risk of atherosclerotic disease; the combined use of these two active agents is described in U.S. Patent No. 5,846,966.
- ezetimibe can be given orally once daily, like HMG-CoA reductase inhibitors such as simvastatin, it would be beneficial to combine the two active agents into a single orally administerable pharmaceutical dosage unit such as a tablet using a formulation that is stable and minimizes the degradation of the active agents.
- the instant invention addresses this need by providing a novel formulation for bulk pharmaceutical composition and for oral pharmaceutical dosage units comprised of simvastatin and ezetimibe that can be produced in a robust process that provides a high quality finished product with minimal unwanted degradation byproducts and desirable shelf -life stability.
- the instant invention provides a novel pharmaceutical formulation comprised of a cholesterol absorption inhibitor and an HMG-CoA reductase inhibitor having desirable stability but which does not require the presence of ascorbic acid, nor does it require the presence of pre-gelatinized starch.
- the instant invention provides a pharmaceutical composition comprised of from 1% to 20% by weight of a cholesterol absorption inhibitor such as ezetimibe; from 1% to 80% by weight of an HMG-CoA reductase inhibitor such as simvastatin; and from 0.01% to 2% by weight of a stabilizing agent such as BHA. It further comprises from 1% to 80% by weight of microcrystalline cellulose; from 0.5% to 10% by weight of hydroxypropyl methylcellulose; from 0.1% to 4% by weight of magnesium stearate; and from 25% to 70% by weight of lactose.
- the composition may also optionally be comprised of one or more of croscarmellose sodium, citric acid, ascorbic acid and propyl gallate.
- composition can include ascorbic acid, it is not necessary to include ascorbic acid in order to obtain desirable results.
- composition could include pre-gelatinized starch, the composition need not include pre-gelatinized starch to obtain desirable results.
- the composition can be prepared in bulk form and is suitable for forming into individual oral dosage units, such as tablets, which are useful for treating vascular conditions such as hyperlipidemia including hypercholesterolemia and treating and preventing atherosclerotic disease and events such as myocardial infarction.
- Another aspect of the present invention is a pharmaceutical composition
- a pharmaceutical composition comprising from 1 to 20% by weight of a cholesterol absorption inhibitor such as ezetimibe; from 1 to 80% by weight of at least one HMG-CoA reductase inhibitor; and from 0.005 to 10% by weight of at least one stabilizing agent. Additional aspects will be evident from the following detailed description.
- the instant invention is directed to formulations of HMG-CoA reductase inhibitors and cholesterol absorption inhibitors.
- HMG-CoA reductase inhibitor is a statin, including, for example, simvastatin, lovastatin, atorvastatin, fluvastatin, pravastatin, cerivastatin, pitavastatin and rosuvastatin.
- the cholesterol absorption inhibitor may be selected from any of those disclosed in U.S. Patents Nos.
- Simvastatin is marketed worldwide, and sold in the U.S. under the tradename ZOCOR®. Methods for making it are described in U.S Patent No.'s 4,444,784; 4,916,239; 4,820,850; among other patent and literature publications. Simvastatin is shown below as structural formula I:
- Ezetimibe is now marketed in the U.S. under the tradename ZETIA®.
- the ZETIA® formulation contains ezetimibe as the only active ingredient.
- Methods for making ezetimibe are described in U.S. Patent No.'s 5,631,365; Re. 37721; 5,846,966; 5,767,115, 6,207,822; U.S. Application No. 10/105,710 filed March 25, 2002 and PCT No. 93/02048.
- Ezetimibe is shown below as structural formula U, and can be in an anhydrous or hydrated form:
- the instant oral pharmaceutical composition may contain one or more of microcrystalline cellulose, hydroxypropyl methylcellulose (HPMC), magnesium stearate, lactose and povidone (PVP).
- HPMC hydroxypropyl methylcellulose
- PVP povidone
- the composition is also comprised of one or more stabilizing agents including antioxidant agents such as, for example, butylated hydroxyanisole (BHA), 2,6-di-tert-butyl-4-methylphenol (BHT), propyl gallate, ascorbic acid, citric acid, edetate disodium and calcium metabisulphite, with BHA, propyl gallate and combinations thereof being preferred, and a combination of BHA with propyl gallate being most preferred.
- antioxidant agents such as, for example, butylated hydroxyanisole (BHA), 2,6-di-tert-butyl-4-methylphenol (BHT), propyl gallate, ascorbic acid, citric acid, edetate disodium and calcium metabisulphite, with BHA, propyl gallate and combinations thereof being preferred, and a combination of BHA with propyl gallate being most preferred.
- BHA butylated hydroxyanisole
- BHT 2,6-di-tert-butyl-4-methylphenol
- the composition does not require the presence of ascorbic acid as a component to achieve good results.
- the composition does not require the presence of pregelatinized starch as a component to achieve good results, although pregelatinized starch could be included in the composition if desired.
- ascorbic acid it is intended to include the free acid as well as salt forms thereof, such as sodium ascorbate. It is known that ascorbic acid tends to discolor compositions, pharmaceutical and otherwise, when it is a component. When used in pharmaceutical tablets, this discoloring effect may necessitate the use of a coating over the tablet to mask the discoloration.
- composition of this invention can be formulated without ascorbic acid, such tablets formed without ascorbic acid can be prepared without the extra step of adding a film coating.
- a film coating could be added if desired, for example for aesthetic purposes, but the need to add a coating to mask the discoloration caused by ascorbic acid is removed.
- compositions encompass both the bulk composition and individual oral dosage units (tablets, pills and the like) comprised of the two pharmaceutically active agents, e.g. simvastatin and ezetimibe, with the pharmaceutically inactive excipients described herein (the active agents and the excipients are collectively referred to herein as the "components" of the composition).
- the bulk composition is material that has not yet been formed into individual oral dosage units.
- the oral dosage unit form of the pharmaceutical composition is preferably a tablet.
- the total weight of a single oral dosage unit e.g. the weight of one tablet, is determined by adding the weights of all the components (i.e., the two active agents and the excipients) in the dosage unit, and does not include the weight of any coatings which may optionally be externally applied to the dosage unit after it has been formed from the bulk composition. It also does not include any solvents used during the granulation process which are subsequently removed during drying.
- the total weight of a single oral dosage unit as defined above is used as the basis for calculating the weight percentage of each of the components that comprise the dosage unit.
- dosage units comprised of the components described herein that are uncoated as well as those that are coated with waxes, colorants, and the like are included within the scope of this invention.
- the total weight of the bulk composition comprised of the components described herein will necessarily vary according to the amount of bulk composition that is desired to be produced. For the purpose of calculating the weight percentage of each of the components that comprise any given amount of bulk composition, the weights of all the components (i.e., the two active agents and the excipients) in a given amount of bulk composition are added together to determine the total weight of the bulk composition. As would be understood in the art, the bulk composition would not contain either solvents used in the granulation process, nor coating materials as components, and therefore such coating materials and solvents would not be included in the total weight calculation of the bulk composition.
- component weight ranges and specific weight amounts used herein to describe the composition of a single oral dosage unit can be scaled proportionally to make bulk composition.
- component weight percentage amounts used herein are applicable to either individual oral dosage units or to bulk composition.
- the total weight of the pharmaceutical dosage unit can be varied as desired, for reasons of practicality it is preferable for the total weight of a single oral dosage unit to be in the range from 50 mg to lOOOmg, and particularly from 100 mg to 800 mg.
- the pharmaceutical composition is comprised of the cholesterol absorption inhibitor active agent, such as ezetimibe, in an amount that is from 1% to 20% by weight of the composition, and particularly from 1.25% to 10%; the HMG-CoA reductase inhibitor active agent, such as simvastatin, in an amount that is from 1% to 80% by weight of the composition, particularly from 1% to 20%, and more particularly from 5% to 10%; and at least one stabilizing agent, such as BHA, in an amount that is from 0.005% to 20% by weight, particularly from 0.01% to 2%, more particularly from 0.01% to 0.05%, and most particularly about 0.02%.
- the cholesterol absorption inhibitor active agent such as ezetimibe
- HMG-CoA reductase inhibitor active agent such as si
- the composition further comprises from 0% to 0.2% (i.e., 0.2% or less), particularly from 0.001% to 0.05%, and most particularly about 0.005% by weight of propyl gallate.
- an oral dosage unit having a total weight in the range from lOOmg to 800 mg may be comprised of from 1.25% to 10% by weight of ezetimibe, from 5 to 10% by weight of simvastatin, about 0.02% of BHA, and optionally about 0.005% by weight of propyl gallate.
- the pharmaceutical composition for example but not limited to an oral dosage unit having a total weight in the range from lOOmg to 800mg, is further comprised of the percent amounts by weight of the following excipients: from 1% to 80%, particularly from 5% to 20%, and most particularly about 15% of microcrystalline cellulose; from 0.5% to 10%, particularly from 1% to 4%, and most particularly about 2% of HPMC; and from 0.1% to 4%, particularly from 0.5% to 2%, and most particularly about 1.5% of magnesium stearate.
- Lactose is also a component of the composition and can be used in varying amounts to achieve the desired total tablet weight. For example, if for a single dosage unit, the combined weight of all the components other than lactose is 36.77 mg, then 63.23 mg of lactose can be added to achieve a total dosage unit weight of 100 mg. If for a single dosage unit, the combined weight of all the components other than lactose is 73.54 mg, then 126.46 mg of lactose can be added to achieve a total dosage unit weight of 200 mg. As would be understood in the art, such component weight amounts can be scaled up proportionally to make bulk composition. Generally, about 25% to 70% by weight of the composition is comprised of lactose.
- croscarmellose sodium may optionally be included as a component in the composition. Accordingly, from 0% to
- croscarmellose sodium may be included in the composition.
- citric acid may optionally be included as a component in the composition. Accordingly, from 0% to 10% (i.e., 10% or less), particularly from 0.1% to 1.25%, and most particularly about 0.25% by weight of citric acid may be included in the composition.
- lactic acid malic acid, succinic acid, tartaric acid and EDTA may optionally be included in the composition.
- the pharmaceutical composition is comprised of from 1% to 20% by weight of the composition of a cholesterol absorption inhibitor, such as ezetimibe; from 1% to 80% by weight of the composition of at least one HMG-CoA reductase inhibitor, such as a statin; and at least one stabilizing agent in an amount that is from 0.005% to 10% by weight of the composition, and particularly from 0.01% to 5%, and more particularly from 0.01% to 2%.
- a cholesterol absorption inhibitor such as ezetimibe
- HMG-CoA reductase inhibitor such as a statin
- stabilizing agent in an amount that is from 0.005% to 10% by weight of the composition, and particularly from 0.01% to 5%, and more particularly from 0.01% to 2%.
- the stabilizing agent is an antioxidant.
- the antioxidant is selected from the group consisting of butylated hydroxyanisole, citric acid and edetate disodium and mixtures thereof.
- the composition further comprises one or more components selected from the group consisting of sodium lauryl sulfate, croscarmellose sodium, povidone, microcrystalline cellulose and lactose monohydrate.
- an oral dosage unit comprised of from 5 mg to 20 mg, and particularly 10 mg, of ezetimibe; from 5 mg to 80 mg, and particularly a dosage amount selected from 5 mg, 10 mg, 20 mg, 40 mg and 80 mg, of simvastatin; and from 0.002 mg to 0.004 mg of BHA per mg of simvastatin. More particularly, the composition also optionally comprises from 0.0005 mg to 0.001 mg of propyl gallate per mg of simvastatin.
- the composition can be comprised of from 0.01 mg to 16 mg, and particularly from 0.02 mg to 0.16 mg of BHA, and additionally may be comprised of from O.OOlmg to 0.05 mg, and particularly from 0.005 mg to 0.04 mg of propyl gallate. Although not required, inclusion of propyl gallate in the composition is preferred.
- the dosage unit additionally comprises from 1 mg to 640 mg, and particularly from 15 mg to 120 mg of microcrystalline cellulose; from 0.5 mg to 80 mg, and particularly from 2 mg to 16 mg of HPMC; from 0.1 mg to 32 mg, and particularly from 1.5 to 12 mg of magnesium stearate; and lactose.
- the amount of lactose in a dosage unit is a matter of choice, and can be selected to achieve the desired total tablet weight. Generally, about 1000 mg or less of lactose per dosage unit, for example from about 25 mg to 1000 mg, may be used to produce a dosage unit of practicable size.
- croscarmellose sodium may optionally be included as a component in the composition.
- an oral dosage unit may contain from 0 mg to 80 mg (i.e., 80 mg or less) of croscarmellose sodium, and particularly from 3 mg to 24 mg of croscarmellose sodium.
- citric acid may optionally be included as a component in the composition.
- an oral dosage unit may contain from 0 mg to 80 mg (i.e., 80 mg or less), and particularly from 0.25 mg to 2 mg of citric acid.
- one or more of lactic acid, malic acid, succinic acid, tartaric acid and EDTA may optionally be included in the dosage unit.
- a method of treating one or more diseases associated with a vascular condition in a patient in need of such treatment by administering to the patient a therapeutically effective amount of a pharmaceutical composition of this invention.
- a method of treating one or more diseases associated with a vascular condition in a patient in need of such treatment by administering to the patient a therapeutically effective amount of a pharmaceutical composition of this invention.
- the amount of ezetimibe per dosage unit is 10 mg
- the amount of simvastatin per dosage unit is selected from:
- simvastatin is from 1% to 20%, and particularly 5% by weight of the composition
- simvastatin is from 1% to 20%, and particularly 10% by weight of the composition
- simvastatin is from 4 % to 20%, and particularly 10% by weight of the composition; and (e) 80 mg, wherein simvastatin is from 8% to 20%, and particularly 10% by weight of the composition.
- the amount of simvastatin when the amount of simvastatin is 5% by weight of the composition, then the amount of ezetimibe is 10% by weight of the composition, and when the amount of simvastatin is 10% by weight of the composition, then the amount of ezetimibe is selected from:
- composition (d) 1 % to 20%, and particularly 1.25% by weight of the composition.
- BHA and propyl gallate are included within the composition.
- ascorbic acid is absent from the composition.
- ascorbic acid is absent from the composition, and tablet dosage units formed from the bulk composition do not have a film coating over the tablets.
- pregelatinized starch is absent from the composition.
- pregelatinized starch and ascorbic acid are both absent from the composition.
- pregelatinized starch and ascorbic acid are both absent from the composition, and BHA and propyl gallate are both included within the composition.
- An example within the scope of this invention includes a composition comprised of ezetimibe, simvastatin, BHA and propyl gallate, wherein absent from the composition are one or both of ascorbic acid and pregelatinized starch.
- a further example includes a tablet pharmaceutical dosage unit comprised of ezetimibe, simvastatin, BHA and propyl gallate, wherein ascorbic acid and a film coating over the tablet are both absent from the dosage unit, or more particularly wherein ascorbic acid, pregelatinized starch and a film coating over the tablet are all absent from the dosage unit.
- a granulating fluid is used to agglomerate the bulk powders to improve the processing properties of the bulk material.
- a mixture of ethanol and water is suitable to use as the granulating fluid.
- Varying proportions of wate ⁇ ethanol can be used, for example in the range of 10:1 to 1:3 water to ethanol on a volumetric basis.
- the granulating fluid is a 3: 1 ratio, on a volumetric basis, of water to ethanol.
- the total quantity of granulating fluid added can be varied depending on the scale of the operation.
- a usual range for the granulating fluid as used with the instant composition is from about 15 to 30% by weight of the composition, and particularly about 25%.
- the granulating fluid is removed using techniques known in the art such as tray drying, fluid bed drying, microwave drying and vacuum drying prior to compression of the bulk material into tablets.
- the instant pharmaceutical composition in bulk and tablet form can be prepared by the following process.
- the lactose, microcrystalline cellulose, simvastatin, ezetimibe, hydroxypropyl methylcellulose and croscarmellose sodium are mixed in a high shear mixer granulator to ensure uniform distribution of each component.
- the granulating solvent is prepared by dissolving the BHA and propyl gallate in ethanol and the citric acid is dissolved in water.
- the water and ethanol solutions are then mixed and sprayed onto the powder bed in the high shear mixer granulator.
- the resultant wet mass is then dried and screened. It is then lubricated by the addition of magnesium stearate.
- the final lubricated powder blend is compressed into tablets.
- oral dosage units described in Examples 1-6 can be made from appropriately scaled bulk composition using the process described above.
- Ezetimibe Granulation BHA and citric acid in the amounts described above for the ezetimibe granulation were dissolved in a 70:30 water/alcohol mixture.
- Povidone (PVP) and ascorbic acid in the amounts described above for the ezetimibe granulation were dissolved in water.
- the ezetimibe, lactose, half of the croscarmellose sodium and half of the microcrystalline cellulose in the amounts described above for the ezetimibe granulation were mixed in a Hobart mixer. While blending, the BHA solution described above was added to the ezetimibe mixture. The resulting mixture was granulated using the povidone/ascorbic acid solution described above.
- the resulting wet mass was granulated as described above and then blended with the other half of the croscarmellose sodium and microcrystalline cellulose.
- Simvastatin Granulation BHA and citric acid in the amounts described above for the simvastatin granulation were dissolved in a 7:3 water/alcohol mixture.
- Povidone (PVP) and ascorbic acid in the amounts described above for the simvastatin granulation were dissolved in water.
- the simvastatin, lactose, half of the croscarmellose sodium and half of the microcrystalline cellulose in the amounts described above for the simvastatin granulation were mixed in a Hobart mixer. While blending, the BHA solution described above was added to the simvastatin mixture. The resulting mixture was granulated using the povidone/ascorbic acid solution described above.
- the resulting wet mass was granulated as described above and then blended with the other half of the croscarmellose sodium and microcrystalline
- Composite Granules The ezetimibe granules and simvastatin granules were mixed together in a Turbula mixer. Magnesium stearate was mixed with the granule mixture and compressed into tablets in a manner similar to that described above.
- the present invention provides a therapeutic combination comprising (a) a first amount of from 1% to 20% by weight of at least one sterol absorption inhibitor or a pharmaceutically acceptable salt thereof or a solvate thereof and from 0.005% to 10% by weight of at least one first stabilizing agent; and (b) a second amount of from 1% to 80% by weight of at least one HMG CoA reductase inhibitor and from 0.005% to 10% by weight of at least one second stabilizing agent, wherein the first amount and the second amount together comprise a therapeutically effective amount for the treatment or prevention of atherosclerosis.
- the first stabilizing agent and the second stabilizing agent can be the same or chemically different and include for example the stabilizing agents listed above.
- therapeutic combination means the administration of two or more therapeutic agents, such as sterol absorption inhibitor(s) and HMG CoA reductase inhibitor(s), to prevent or treat atherosclerosis or any of its associated conditions, such as are discussed above.
- Such administration includes coadministration of these therapeutic agents in a substantially simultaneous manner, such as in a single tablet or capsule having a fixed ratio of active ingredients or in multiple, separate capsules for each therapeutic agent.
- such administration includes use of each type of therapeutic agent in a sequential manner. In either case, the treatment using the combination therapy will provide beneficial effects in treating the atherosclerotic condition.
- a potential advantage of the combination therapy disclosed herein may be a reduction in the required amount of an individual therapeutic compound or the overall total amount of therapeutic compounds that are effective in treating the atherosclerotic condition.
- the side effects of the individual compounds can be reduced as compared to a monotherapy, which can improve patient compliance.
- therapeutic agents can be selected to provide a broader range of complimentary effects or complimentary modes of action.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
Abstract
Description
Claims
Priority Applications (27)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60320652T DE60320652T2 (en) | 2002-07-26 | 2003-07-22 | COMPOSITION FREE OF ASCORBIC ACID, CONTAINING AN INHIBITOR OF CHOLESTERINE ABSORPTION, AN INHIBITOR OF HMG-COA REDUCTASE AND A STABILIZER |
JP2004524692A JP2005538104A (en) | 2002-07-26 | 2003-07-22 | Composition comprising cholesterol absorption inhibitor, HMG-CoA reductase inhibitor and stabilizer |
MXPA05001004A MXPA05001004A (en) | 2002-07-26 | 2003-07-22 | Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent. |
MEP-2008-308A ME00207B (en) | 2002-07-26 | 2003-07-22 | Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent |
DK03771709T DK1531805T3 (en) | 2002-07-26 | 2003-07-22 | Composition without ascorbic acid comprising a cholesterol absorption inhibitor, an HMG-CoA reductase inhibitor and a stabilizer |
EA200500279A EA008888B1 (en) | 2002-07-26 | 2003-07-22 | Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent |
BR0312933-0A BR0312933A (en) | 2002-07-26 | 2003-07-22 | Pharmaceutical composition, pharmaceutical dosage unit, method for treating one or more diseases associated with a vascular condition, and therapeutic combination. |
MEP-2008-47A ME00008B (en) | 2002-07-26 | 2003-07-22 | Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent |
AU2003261217A AU2003261217B2 (en) | 2002-07-26 | 2003-07-22 | Composition comprising a cholesterol absorption inhibitor, an HMG-CoA reductase inhibitor and a stabilizing agent |
SI200331222T SI1531805T1 (en) | 2002-07-26 | 2003-07-22 | Composition devoid of ascorbic acid comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent |
UAA200501756A UA82489C2 (en) | 2002-07-26 | 2003-07-22 | Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent (variants), treatment method |
IL16627903A IL166279A0 (en) | 2002-07-26 | 2003-07-22 | Composition comprising a cholesterol absorption inhibitor an HMG-COA reductase inhibitor and a stabilizing agent |
MEP-308/08A MEP30808A (en) | 2002-07-26 | 2003-07-22 | Composition comprising a cholesterol absorption inhibitor, an hmgcoa reductase inhibitor and a stabilizing agent |
CA002493076A CA2493076A1 (en) | 2002-07-26 | 2003-07-22 | Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent |
NZ537611A NZ537611A (en) | 2002-07-26 | 2003-07-22 | Composition comprising a cholesterol absorption inhibitor, an HMG-CoA reductase inhibitor and a stabilizing agent |
YUP-2005/0061A RS50419B (en) | 2002-07-26 | 2003-07-22 | Composition devoid of ascorbic acid comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent |
EP03771709A EP1531805B1 (en) | 2002-07-26 | 2003-07-22 | Composition devoid of ascorbic acid comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent |
IS7637A IS7637A (en) | 2002-07-26 | 2005-01-10 | Composition comprising cholesterol uptake inhibitor, HMG-COA reductase inhibitor and binder |
HR20050081A HRP20050081A2 (en) | 2002-07-26 | 2005-01-25 | Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent |
TNP2005000022A TNSN05022A1 (en) | 2002-07-26 | 2005-01-26 | Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent |
NO20051033A NO20051033L (en) | 2002-07-26 | 2005-02-25 | Composition comprising a cholesterol absorption inhibitor, an HMF-CoA reductase inhibitor and a stabilizing agent |
HK06100504A HK1080384A1 (en) | 2002-07-26 | 2006-01-12 | Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent |
NO20082156A NO20082156L (en) | 2002-07-26 | 2008-05-08 | Composition comprising a cholesterol absorption inhibitor, an HMG-CoA reductase inhibitor and a stabilizing agent |
IL191348A IL191348A0 (en) | 2002-07-26 | 2008-05-11 | Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent |
IS8753A IS8753A (en) | 2002-07-26 | 2008-07-28 | Composition comprising cholesterol uptake inhibitor, HMG-CoA reductase inhibitor and binder |
HR20080518A HRP20080518A2 (en) | 2002-07-26 | 2008-10-16 | Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent |
AU2009200768A AU2009200768A1 (en) | 2002-07-26 | 2009-02-26 | Composition comprising a cholesterol absorption inhibitor, an HMG-CoA reductase inhibitor and a stabilizing agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39869102P | 2002-07-26 | 2002-07-26 | |
US60/398,691 | 2002-07-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004010993A1 true WO2004010993A1 (en) | 2004-02-05 |
Family
ID=31188454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/022889 WO2004010993A1 (en) | 2002-07-26 | 2003-07-22 | Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent |
Country Status (39)
Country | Link |
---|---|
US (4) | US7229982B2 (en) |
EP (2) | EP1992343A1 (en) |
JP (2) | JP2005538104A (en) |
KR (2) | KR20080070089A (en) |
CN (2) | CN101069684A (en) |
AR (2) | AR040588A1 (en) |
AT (1) | ATE393628T1 (en) |
AU (2) | AU2003261217B2 (en) |
BR (1) | BR0312933A (en) |
CA (1) | CA2493076A1 (en) |
CR (1) | CR9767A (en) |
DE (1) | DE60320652T2 (en) |
DK (1) | DK1531805T3 (en) |
EA (1) | EA008888B1 (en) |
EC (2) | ECSP055573A (en) |
ES (1) | ES2303603T3 (en) |
GE (1) | GEP20084443B (en) |
GT (2) | GT200300149A (en) |
HK (1) | HK1080384A1 (en) |
HR (2) | HRP20050081A2 (en) |
IL (2) | IL166279A0 (en) |
IS (1) | IS7637A (en) |
MA (1) | MA27289A1 (en) |
ME (3) | ME00207B (en) |
MX (1) | MXPA05001004A (en) |
MY (1) | MY148689A (en) |
NO (2) | NO20051033L (en) |
NZ (1) | NZ537611A (en) |
PA (1) | PA8577901A1 (en) |
PE (1) | PE20050128A1 (en) |
PL (1) | PL375065A1 (en) |
PT (1) | PT1531805E (en) |
RS (2) | RS50419B (en) |
SI (1) | SI1531805T1 (en) |
TN (1) | TNSN05022A1 (en) |
TW (2) | TW200412944A (en) |
UA (1) | UA82489C2 (en) |
WO (1) | WO2004010993A1 (en) |
ZA (1) | ZA200500196B (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006025378A1 (en) * | 2004-08-31 | 2006-03-09 | Kowa Co., Ltd. | Remedy for hyperlipemia |
EP1741427A1 (en) * | 2005-07-06 | 2007-01-10 | KRKA, D.D., Novo Mesto | Pharmaceutical composition comprising simvastatin and ezetimibe |
JP2007532532A (en) * | 2004-04-10 | 2007-11-15 | ハンミ ファーム. シーオー., エルティーディー. | Sustained release preparation for oral administration of HMG-CoA reductase inhibitor and method for producing the same |
EP1905424A2 (en) * | 2006-02-02 | 2008-04-02 | Ranbaxy Laboratories Limited | Pharmaceutical composition comprising stabilized statin particles |
US7470678B2 (en) | 2002-07-05 | 2008-12-30 | Astrazeneca Ab | Diphenylazetidinone derivatives for treating disorders of the lipid metabolism |
WO2010021609A1 (en) * | 2008-08-22 | 2010-02-25 | Mahmut Bilgic | Solubility and stability enhancing pharmaceutical formulation |
EP2168573A1 (en) * | 2008-09-30 | 2010-03-31 | LEK Pharmaceuticals D.D. | Formulations comprising ezetimibe |
EP2178515A2 (en) | 2007-07-13 | 2010-04-28 | Generics Ýuk¨Limited | Stable compositions |
EP2204170A1 (en) | 2008-12-01 | 2010-07-07 | LEK Pharmaceuticals D.D. | Pharmaceutical composition comprising ezetimibe and simvastatin |
US7842684B2 (en) | 2006-04-27 | 2010-11-30 | Astrazeneca Ab | Diphenylazetidinone derivatives possessing cholesterol absorption inhibitor activity |
US7871998B2 (en) | 2003-12-23 | 2011-01-18 | Astrazeneca Ab | Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity |
US7893048B2 (en) | 2005-06-22 | 2011-02-22 | Astrazeneca Ab | 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions |
WO2011002422A3 (en) * | 2009-07-02 | 2011-04-28 | Bilgic Mahmut | Solubility enhancing pharmaceutical formulation |
WO2011002424A3 (en) * | 2009-07-02 | 2011-04-28 | Bilgic Mahmut | Solubility and stability enchancing pharmaceutical formulation comprising ezetimibe and simvastatin |
WO2011019326A3 (en) * | 2009-07-02 | 2011-04-28 | Mahmut Bilgic | Solubility and stability enchancing pharmaceutical formulation |
EP2368543A1 (en) | 2010-03-25 | 2011-09-28 | KRKA, tovarna zdravil, d.d., Novo mesto | Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe |
EP3085364A4 (en) * | 2013-12-18 | 2017-08-23 | Alvogen Korea Co., Ltd. | Pharmaceutical combined preparation containing hmg-coa reductase inhibitor and cholesterol absorption inhibitor |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR040588A1 (en) * | 2002-07-26 | 2005-04-13 | Schering Corp | PHARMACEUTICAL FORMULATION INCLUDING AN INHIBITOR OF CHOLESTEROL ABSORPTION AND AN INHIBITOR OF A HMGCO TO REDUCTASE |
US7320972B2 (en) * | 2003-11-10 | 2008-01-22 | Microbia, Inc. | 4-Biarylyl-1-phenylazetidin-2-ones |
EP1849459A1 (en) * | 2006-03-06 | 2007-10-31 | Teva Pharmaceutical Industries Ltd. | Ezetimibe compositions |
EP2526932B1 (en) | 2006-06-19 | 2017-06-07 | Alpharma Pharmaceuticals LLC | Pharmaceutical composition |
CN1994296B (en) * | 2006-08-02 | 2010-06-16 | 浙江京新药业股份有限公司 | Pharmaceutical composition containing simvastatin |
AU2008281640A1 (en) * | 2007-07-27 | 2009-02-05 | Cipla Limited | Pharmaceutical compositions and process for making them |
WO2009024889A2 (en) | 2007-08-21 | 2009-02-26 | Ranbaxy Laboratories Limited | Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe |
AU2008337435A1 (en) * | 2007-12-17 | 2009-06-25 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Suspension comprising non-micronized ezetimibe micro-particles |
US20090233898A1 (en) * | 2008-03-11 | 2009-09-17 | Glenmark Generics Ltd | Pharmaceutical Compositions Comprising Simvastatin and Ezetimibe |
MX344885B (en) * | 2008-11-10 | 2017-01-10 | Psicofarma S A De C V | Process for obtaining a composition of rosuvastatin calcium and product obtained. |
WO2010066687A2 (en) * | 2008-12-11 | 2010-06-17 | Dsm Ip Assets B.V. | Stabalized statin-comprising compositions |
EP2216016A1 (en) | 2009-02-06 | 2010-08-11 | LEK Pharmaceuticals d.d. | Process for the preparation of a pharmaceutical composition comprising ezetimibe |
KR101302243B1 (en) * | 2010-07-28 | 2013-09-02 | 씨제이제일제당 (주) | Pharmaceutical composition comprising Rosuvastatin or the salt thereof |
CN101978953A (en) * | 2010-10-11 | 2011-02-23 | 上海交通大学 | Hygroscopic auxiliary material-based solid preparation |
EP2468258A1 (en) | 2010-12-22 | 2012-06-27 | LEK Pharmaceuticals d.d. | Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient |
US20140141090A1 (en) | 2011-02-02 | 2014-05-22 | Edward S. Wilson | Pharmaceutical Composition Comprising Opioid Agonist And Sequestered Antagonist |
CN102266323B (en) * | 2011-08-04 | 2013-03-27 | 海南锦瑞制药股份有限公司 | Composition of ezetimibe and simvastatin and preparation method thereof |
EP2753309B1 (en) * | 2011-09-08 | 2020-01-01 | Hexal AG | Pharmaceutical compound for oral administration with a statin |
WO2013166114A1 (en) * | 2012-05-01 | 2013-11-07 | Althera Life Sciences, Llc | Oral tablet formulation consisting of fixed combination of atorvastatin and ezetimibe |
MX365046B (en) * | 2012-05-01 | 2019-05-17 | Althera Life Sciencies Llc | Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases. |
RU2547574C2 (en) * | 2013-07-09 | 2015-04-10 | Общество с ограниченной ответственностью "Трейдсервис" | Hypolipidemic dosage form and method for preparing it |
CN103585146B (en) * | 2013-11-09 | 2015-04-01 | 北京中申专利科技有限公司 | Medicine composition of simvastatin |
CN104306348B (en) * | 2014-09-30 | 2017-05-31 | 地奥集团成都药业股份有限公司 | A kind of Simvastatin Tablets and preparation method thereof |
CN108366957A (en) * | 2015-11-06 | 2018-08-03 | 燿石治疗公司 | Lucky Cabbeen for treating angiocardiopathy combines |
CN106937952A (en) * | 2016-01-04 | 2017-07-11 | 重庆华邦制药有限公司 | The preparation of Ezetimibe and Simvastatin |
EP3281649A1 (en) * | 2016-08-09 | 2018-02-14 | Teleflex Lifesciences | Wetting agent formulation |
JP6937195B2 (en) * | 2017-09-01 | 2021-09-22 | 興和株式会社 | Pharmaceutical composition |
CN111601590A (en) * | 2017-11-23 | 2020-08-28 | 浙江海正药业股份有限公司 | Haizumab tablet and preparation method thereof |
US11833133B2 (en) * | 2020-08-13 | 2023-12-05 | Orient Pharma Co., Ltd. | Solid oral pharmaceutical composition |
TWI760067B (en) * | 2020-08-13 | 2022-04-01 | 友霖生技醫藥股份有限公司 | Solid oral pharmaceutical composition |
CN112168801A (en) * | 2020-10-22 | 2021-01-05 | 哈药集团技术中心 | Preparation method of simvastatin tablets |
CN115227659B (en) * | 2022-08-19 | 2023-05-02 | 北京百奥药业有限责任公司 | Ezetimibe simvastatin composition and preparation method thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5366738A (en) * | 1982-07-29 | 1994-11-22 | Merck & Co., Inc. | Controlled release drug dispersion delivery device |
WO1995008532A1 (en) * | 1993-09-21 | 1995-03-30 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
US6218403B1 (en) * | 1996-07-26 | 2001-04-17 | Sanofi-Synthelabo | Antithrombotic and antiatherogenic pharmaceutical composition including a thienopyridine derivative and an HMG-CoA-reductase inhibitor |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
AU1422388A (en) | 1987-01-27 | 1988-08-10 | Warner-Lambert Company | Lipid regulating compositions |
US4820850A (en) | 1987-07-10 | 1989-04-11 | Merck & Co., Inc. | Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof |
US4916239A (en) | 1988-07-19 | 1990-04-10 | Merck & Co., Inc. | Process for the lactonization of mevinic acids and analogs thereof |
US4990535A (en) | 1989-05-03 | 1991-02-05 | Schering Corporation | Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine |
CA2040865C (en) | 1990-05-15 | 2002-07-23 | James L. Bergey | Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor |
US5622985A (en) | 1990-06-11 | 1997-04-22 | Bristol-Myers Squibb Company | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
IL100091A (en) | 1990-12-12 | 1998-08-16 | Zeneca Ltd | Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5688785A (en) | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
US5688787A (en) | 1991-07-23 | 1997-11-18 | Schering Corporation | Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof |
DE69222532T2 (en) | 1991-07-23 | 1998-02-26 | Schering Corp | SUBSTITUTED BETA LACTAM COMPOUNDS AS HYPOCHOLESTEROLEMIC AGENTS AND METHOD FOR THE PRODUCTION THEREOF |
US5162117A (en) | 1991-11-22 | 1992-11-10 | Schering Corporation | Controlled release flutamide composition |
CA2085871C (en) * | 1991-12-27 | 2002-05-07 | Gerald S. Rork | A controlled release drug dispersion delivery device |
LT3300B (en) | 1992-12-23 | 1995-06-26 | Schering Corp | Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor |
LT3595B (en) | 1993-01-21 | 1995-12-27 | Schering Corp | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents |
JPH06247854A (en) * | 1993-02-24 | 1994-09-06 | Ss Pharmaceut Co Ltd | Ascorbic acid-containing composition |
US5976570A (en) | 1993-12-21 | 1999-11-02 | Applied Analytical Industries, Inc. | Method for preparing low dose pharmaceutical products |
US6369103B1 (en) | 1994-01-18 | 2002-04-09 | Bristol-Myers Squibb Company | Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor |
US5627176A (en) | 1994-03-25 | 1997-05-06 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
WO1995035277A1 (en) * | 1994-06-20 | 1995-12-28 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
US6268392B1 (en) * | 1994-09-13 | 2001-07-31 | G. D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors |
AU2453295A (en) | 1994-09-20 | 1996-04-19 | Pfizer Inc. | Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor |
US5633246A (en) | 1994-11-18 | 1997-05-27 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5624920A (en) | 1994-11-18 | 1997-04-29 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5656624A (en) | 1994-12-21 | 1997-08-12 | Schering Corporation | 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents |
AR004701A1 (en) * | 1995-10-31 | 1999-03-10 | Schering Corp | 2-AZETIDINONES SUBSTITUTED WITH SUGARS USEFUL AS HYPOCHOLESTEROLEMIC AGENTS, PHARMACEUTICAL COMPOSITION, PROCESS FOR THE PREPARATION OF SUCH COMPOSITION, USE OF SUCH COMPOUNDS TO MANUFACTURE MEDICINES AND EQUIPMENT. |
EP0904082A4 (en) * | 1996-04-17 | 2001-09-26 | Merck & Co Inc | Combination therapy for reducing the risks associated with cardiovascular disease |
US6673831B1 (en) | 1996-04-17 | 2004-01-06 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardiovascular disease |
AU4326197A (en) | 1996-07-09 | 1998-02-02 | Merck & Co., Inc. | Pharmaceutical compositions |
US5952003A (en) | 1996-08-01 | 1999-09-14 | Novartis Corporation | Terazosin capsules |
US6251852B1 (en) | 1996-09-18 | 2001-06-26 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardiovascular disease |
US6235706B1 (en) | 1996-09-18 | 2001-05-22 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardiovascular disease |
US5756470A (en) | 1996-10-29 | 1998-05-26 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
US6024981A (en) | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
US6245797B1 (en) * | 1997-10-22 | 2001-06-12 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease |
FR2772615B1 (en) * | 1997-12-23 | 2002-06-14 | Lipha | MULTILAYER TABLET FOR INSTANT RELEASE THEN PROLONGED ACTIVE SUBSTANCES |
AU4699099A (en) | 1998-06-24 | 2000-01-10 | Merck & Co., Inc. | Compositions and methods for treating elevated blood cholesterol |
WO1999066929A1 (en) | 1998-06-24 | 1999-12-29 | Merck & Co., Inc. | Compositions and methods for treating elevated blood cholesterol |
US6099865A (en) | 1998-07-08 | 2000-08-08 | Fmc Corporation | Croscarmellose taste masking |
US6268352B1 (en) * | 1998-09-02 | 2001-07-31 | The Regents Of The University Of California | Promoters of neural regeneration |
JP2000109882A (en) * | 1998-10-01 | 2000-04-18 | Nof Corp | Oily powder, its production and use thereof |
SA99191255B1 (en) | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | celecoxib compounds |
US6207822B1 (en) | 1998-12-07 | 2001-03-27 | Schering Corporation | Process for the synthesis of azetidinones |
US6569461B1 (en) | 1999-03-08 | 2003-05-27 | Merck & Co., Inc. | Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors |
EP1163203A1 (en) | 1999-03-08 | 2001-12-19 | Merck & Co., Inc. | Crystalline hydrated dihydroxy open-acid simvastatin calcium salt |
JP2002538202A (en) | 1999-03-08 | 2002-11-12 | メルク エンド カムパニー インコーポレーテッド | Dihydroxy open acid of HMG-CoA reductase inhibitor and salt thereof |
EP1158977B1 (en) | 1999-03-10 | 2005-10-12 | G.D. Searle LLC | Composition for administering a cyclooxygenase-2 inhibitor to animals |
JP2000302672A (en) * | 1999-04-16 | 2000-10-31 | Taisho Pharmaceut Co Ltd | Chewable coated tablet |
JP3732039B2 (en) * | 1999-05-21 | 2006-01-05 | 三菱化学フーズ株式会社 | Tablet composition |
DZ3179A1 (en) | 1999-08-03 | 2001-02-08 | Lilly Icos Llc | Pharmaceutical compositions based on beta-carboline. |
US6328995B1 (en) * | 1999-09-24 | 2001-12-11 | Basf Aktiengesellschaft | Stable vitamin and/or carotenoid products in powder form and process for their production |
AU1756201A (en) | 1999-12-08 | 2001-06-18 | Pharmacia Corporation | Nanoparticulate eplerenone compositions |
AU2276801A (en) | 1999-12-20 | 2001-07-03 | Schering Corporation | Extended release oral dosage composition |
US6248359B1 (en) | 2000-01-05 | 2001-06-19 | Laboratorios Phoenix U.S.A., Inc. | Multi-tablet oxybutynin system for treating incontinence |
DK1267880T4 (en) | 2000-02-29 | 2010-05-17 | Bristol Myers Squibb Co | Entecavir low dose formulation and its use |
WO2002020457A1 (en) * | 2000-09-06 | 2002-03-14 | Merck & Co., Inc. | Dihydroxy open-acid salt of simvastatin |
US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
SK286703B6 (en) * | 2000-12-20 | 2009-03-05 | Schering Corporation | Sugar-substituted 2-azetidinones, pharmaceutical preparation containing these compounds and use thereof |
CA2432145C (en) * | 2000-12-28 | 2010-07-13 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazole derivatives and use thereof in medicines |
IL156422A0 (en) | 2001-01-26 | 2004-01-04 | Schering Corp | The use of substituted azetidinone compounds for the treatment of sitosterolemia |
BR0206644A (en) | 2001-01-26 | 2004-02-25 | Schering Corp | Sterol absorption inhibitor (s) combinations with cardiovascular agent (s) for the treatment of vascular conditions |
JP2004517920A (en) | 2001-01-26 | 2004-06-17 | シェーリング コーポレイション | Combination of sterol absorption inhibitors and blood conditioning agents to treat vascular conditions |
AU2002241956A1 (en) | 2001-01-26 | 2002-08-06 | Schering Corporation | Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
PT1413331E (en) | 2001-01-26 | 2007-12-18 | Schering Corp | Combinations of the peroxisome proliferator-activated receptor (ppar) activator fenofibrate with sterol absorption inhibitor ezetimibe for vascular indications |
DE60206365T2 (en) | 2001-03-28 | 2006-07-06 | Schering Corporation, Kenilworth | PROCESS FOR THE ENANTIOSELECTIVE SYNTHESIS OF AZETIDINONE INTERMEDIATE PRODUCTS |
AR040588A1 (en) * | 2002-07-26 | 2005-04-13 | Schering Corp | PHARMACEUTICAL FORMULATION INCLUDING AN INHIBITOR OF CHOLESTEROL ABSORPTION AND AN INHIBITOR OF A HMGCO TO REDUCTASE |
-
2003
- 2003-07-16 AR AR20030102560A patent/AR040588A1/en unknown
- 2003-07-17 MY MYPI20032695A patent/MY148689A/en unknown
- 2003-07-21 PE PE2003000726A patent/PE20050128A1/en not_active Application Discontinuation
- 2003-07-22 EA EA200500279A patent/EA008888B1/en not_active IP Right Cessation
- 2003-07-22 SI SI200331222T patent/SI1531805T1/en unknown
- 2003-07-22 US US10/625,004 patent/US7229982B2/en not_active Expired - Fee Related
- 2003-07-22 MX MXPA05001004A patent/MXPA05001004A/en active IP Right Grant
- 2003-07-22 IL IL16627903A patent/IL166279A0/en unknown
- 2003-07-22 ME MEP-2008-308A patent/ME00207B/en unknown
- 2003-07-22 UA UAA200501756A patent/UA82489C2/en unknown
- 2003-07-22 NZ NZ537611A patent/NZ537611A/en not_active IP Right Cessation
- 2003-07-22 KR KR1020087017824A patent/KR20080070089A/en not_active Application Discontinuation
- 2003-07-22 ES ES03771709T patent/ES2303603T3/en not_active Expired - Lifetime
- 2003-07-22 RS YUP-2005/0061A patent/RS50419B/en unknown
- 2003-07-22 CN CNA2007100850256A patent/CN101069684A/en active Pending
- 2003-07-22 DK DK03771709T patent/DK1531805T3/en active
- 2003-07-22 PA PA20038577901A patent/PA8577901A1/en unknown
- 2003-07-22 BR BR0312933-0A patent/BR0312933A/en not_active IP Right Cessation
- 2003-07-22 CA CA002493076A patent/CA2493076A1/en not_active Abandoned
- 2003-07-22 WO PCT/US2003/022889 patent/WO2004010993A1/en active Application Filing
- 2003-07-22 EP EP08103776A patent/EP1992343A1/en not_active Withdrawn
- 2003-07-22 GT GT200300149A patent/GT200300149A/en unknown
- 2003-07-22 GT GT200300149AK patent/GT200300149AA/en unknown
- 2003-07-22 KR KR1020057001458A patent/KR20050045993A/en not_active Application Discontinuation
- 2003-07-22 DE DE60320652T patent/DE60320652T2/en not_active Revoked
- 2003-07-22 JP JP2004524692A patent/JP2005538104A/en active Pending
- 2003-07-22 EP EP03771709A patent/EP1531805B1/en not_active Revoked
- 2003-07-22 ME MEP-308/08A patent/MEP30808A/en unknown
- 2003-07-22 ME MEP-2008-47A patent/ME00008B/en unknown
- 2003-07-22 PL PL03375065A patent/PL375065A1/en not_active Application Discontinuation
- 2003-07-22 RS RSP-2008/0072A patent/RS20080072A/en unknown
- 2003-07-22 GE GEAP8662A patent/GEP20084443B/en unknown
- 2003-07-22 CN CNB038178443A patent/CN1310643C/en not_active Expired - Fee Related
- 2003-07-22 PT PT03771709T patent/PT1531805E/en unknown
- 2003-07-22 AT AT03771709T patent/ATE393628T1/en not_active IP Right Cessation
- 2003-07-22 AU AU2003261217A patent/AU2003261217B2/en not_active Ceased
- 2003-07-25 TW TW092120442A patent/TW200412944A/en unknown
- 2003-07-25 TW TW097131985A patent/TW200906388A/en unknown
-
2005
- 2005-01-10 ZA ZA200500196A patent/ZA200500196B/en unknown
- 2005-01-10 IS IS7637A patent/IS7637A/en unknown
- 2005-01-25 HR HR20050081A patent/HRP20050081A2/en not_active Application Discontinuation
- 2005-01-25 EC EC2005005573A patent/ECSP055573A/en unknown
- 2005-01-26 TN TNP2005000022A patent/TNSN05022A1/en unknown
- 2005-02-11 MA MA28095A patent/MA27289A1/en unknown
- 2005-02-25 NO NO20051033A patent/NO20051033L/en unknown
-
2006
- 2006-01-12 HK HK06100504A patent/HK1080384A1/en not_active IP Right Cessation
-
2007
- 2007-03-12 US US11/716,595 patent/US20070160666A1/en not_active Abandoned
-
2008
- 2008-02-26 CR CR9767A patent/CR9767A/en unknown
- 2008-02-28 EC EC20080055732008005573A patent/ECSP085573A/en unknown
- 2008-03-12 US US12/047,223 patent/US20080275020A1/en not_active Abandoned
- 2008-05-08 NO NO20082156A patent/NO20082156L/en not_active Application Discontinuation
- 2008-05-11 IL IL191348A patent/IL191348A0/en unknown
- 2008-06-09 JP JP2008150227A patent/JP2008291034A/en not_active Withdrawn
- 2008-06-17 AR ARP080102576A patent/AR067030A2/en not_active Application Discontinuation
- 2008-10-16 HR HR20080518A patent/HRP20080518A2/en not_active Application Discontinuation
-
2009
- 2009-02-26 AU AU2009200768A patent/AU2009200768A1/en not_active Abandoned
- 2009-05-26 US US12/472,021 patent/US7718643B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5366738A (en) * | 1982-07-29 | 1994-11-22 | Merck & Co., Inc. | Controlled release drug dispersion delivery device |
WO1995008532A1 (en) * | 1993-09-21 | 1995-03-30 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
US6218403B1 (en) * | 1996-07-26 | 2001-04-17 | Sanofi-Synthelabo | Antithrombotic and antiatherogenic pharmaceutical composition including a thienopyridine derivative and an HMG-CoA-reductase inhibitor |
Non-Patent Citations (4)
Title |
---|
ARTHUR H KIBBE: "Handbook of Pharmaceutical Excipients-3rd Edition", PHARMACEUTICAL PRESS, XP002258396 * |
DAVIDSON MICHAEL ET AL: "Ezetimibe co-administered with simvastatin in 668 patients with primary hypercholesterolemia", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 39, no. 5 Supplement A, 6 March 2002 (2002-03-06), 51st Annual Scientific Session of the American College of Cardiology;Atlanta, GA, USA; March 17-20, 2002, pages 226A - 227A, XP009019354, ISSN: 0735-1097 * |
DAVIDSON MICHAEL H ET AL: "Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia.", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 40, no. 12, 18 December 2002 (2002-12-18), pages 2125 - 2134, XP001155704, ISSN: 0735-1097 (ISSN print) * |
GAGNE C ET AL: "EFFICACY AND SAFETY OF EZETIMIBE COADMINISTERED WITH ATORVASTATIN OR SIMVASTATIN IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA", CIRCULATION, AMERICAN HEART ASSOCIATION, DALLAS, TX, US, vol. 105, no. 21, 28 May 2002 (2002-05-28), pages 2469 - 2475, XP001132086, ISSN: 0009-7322 * |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7470678B2 (en) | 2002-07-05 | 2008-12-30 | Astrazeneca Ab | Diphenylazetidinone derivatives for treating disorders of the lipid metabolism |
US7871998B2 (en) | 2003-12-23 | 2011-01-18 | Astrazeneca Ab | Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity |
JP4740945B2 (en) * | 2004-04-10 | 2011-08-03 | ハンミ・ホールディングス・カンパニー・リミテッド | Sustained release preparation for oral administration of HMG-CoA reductase inhibitor and method for producing the same |
JP2007532532A (en) * | 2004-04-10 | 2007-11-15 | ハンミ ファーム. シーオー., エルティーディー. | Sustained release preparation for oral administration of HMG-CoA reductase inhibitor and method for producing the same |
US8475840B2 (en) | 2004-04-10 | 2013-07-02 | Hanmi Science Co., Ltd | Sustained release formulation for oral administration of HMG-CoA reductase inhibitor and method for the preparation thereof |
WO2006025378A1 (en) * | 2004-08-31 | 2006-03-09 | Kowa Co., Ltd. | Remedy for hyperlipemia |
JPWO2006025378A1 (en) * | 2004-08-31 | 2008-05-08 | 興和株式会社 | Antihyperlipidemic agent |
JP4886516B2 (en) * | 2004-08-31 | 2012-02-29 | 興和株式会社 | Antihyperlipidemic agent |
US7893048B2 (en) | 2005-06-22 | 2011-02-22 | Astrazeneca Ab | 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions |
WO2007003365A1 (en) * | 2005-07-06 | 2007-01-11 | Krka | Pharmaceutical composition comprising simvastatin and ezetimibe |
NO340496B1 (en) * | 2005-07-06 | 2017-05-02 | Krka Dd Novo Mesto | Pharmaceutical composition comprising simvastatin and ezetimibe, and use in the manufacture of medicaments |
EA013266B1 (en) * | 2005-07-06 | 2010-04-30 | Крка, Товарна Здравил, Д.Д., Ново Место | Pharmaceutical composition comprising simvistatin and ezetimibe |
US8921352B2 (en) | 2005-07-06 | 2014-12-30 | Krka | Pharmaceutical composition comprising simvastatin and ezetimibe |
EP1741427A1 (en) * | 2005-07-06 | 2007-01-10 | KRKA, D.D., Novo Mesto | Pharmaceutical composition comprising simvastatin and ezetimibe |
EP1905424A3 (en) * | 2006-02-02 | 2008-04-30 | Ranbaxy Laboratories Limited | Process for the preparation of a pharmaceutical composition comprising stabilized statin particles |
EP1905424A2 (en) * | 2006-02-02 | 2008-04-02 | Ranbaxy Laboratories Limited | Pharmaceutical composition comprising stabilized statin particles |
US7842684B2 (en) | 2006-04-27 | 2010-11-30 | Astrazeneca Ab | Diphenylazetidinone derivatives possessing cholesterol absorption inhibitor activity |
EP2178515A2 (en) | 2007-07-13 | 2010-04-28 | Generics Ýuk¨Limited | Stable compositions |
WO2010021609A1 (en) * | 2008-08-22 | 2010-02-25 | Mahmut Bilgic | Solubility and stability enhancing pharmaceutical formulation |
EP2168573A1 (en) * | 2008-09-30 | 2010-03-31 | LEK Pharmaceuticals D.D. | Formulations comprising ezetimibe |
AU2009299855B2 (en) * | 2008-09-30 | 2016-05-19 | Lek Pharmaceuticals D.D. | Formulations comprising ezetimibe |
WO2010037728A3 (en) * | 2008-09-30 | 2010-06-10 | Lek Pharmaceuticals D.D. | Formulations comprising ezetimibe |
WO2010037728A2 (en) | 2008-09-30 | 2010-04-08 | Lek Pharmaceuticals D.D. | Novel ezetimibe formulations |
EP2204170A1 (en) | 2008-12-01 | 2010-07-07 | LEK Pharmaceuticals D.D. | Pharmaceutical composition comprising ezetimibe and simvastatin |
WO2011002424A3 (en) * | 2009-07-02 | 2011-04-28 | Bilgic Mahmut | Solubility and stability enchancing pharmaceutical formulation comprising ezetimibe and simvastatin |
WO2011002422A3 (en) * | 2009-07-02 | 2011-04-28 | Bilgic Mahmut | Solubility enhancing pharmaceutical formulation |
WO2011019326A3 (en) * | 2009-07-02 | 2011-04-28 | Mahmut Bilgic | Solubility and stability enchancing pharmaceutical formulation |
EP2368543A1 (en) | 2010-03-25 | 2011-09-28 | KRKA, tovarna zdravil, d.d., Novo mesto | Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe |
WO2011116973A1 (en) | 2010-03-25 | 2011-09-29 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe |
EP3085364A4 (en) * | 2013-12-18 | 2017-08-23 | Alvogen Korea Co., Ltd. | Pharmaceutical combined preparation containing hmg-coa reductase inhibitor and cholesterol absorption inhibitor |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1531805B1 (en) | Composition devoid of ascorbic acid comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent | |
CA2751313C (en) | Process for the preparation of a pharmaceutical composition comprising ezetimibe | |
WO2009024889A2 (en) | Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe | |
KR100202154B1 (en) | Film coated tablet of paracetamol and domperidone | |
WO2010127205A2 (en) | Fixed dose drug combination formulations | |
WO2008075320A2 (en) | Antilipidemic pharmaceutical compositions and process for preparation thereof | |
WO2005011642A1 (en) | Single unit pharmaceutical composition comprising a mixture of a fibrate and an homocysteine reducing agent | |
JP4741581B2 (en) | Composition for the treatment of hyperlipidemia | |
AU2005210117A1 (en) | Hypocholesterolemic compositions comprising a statin and an antiflatulent agent | |
KR20120120519A (en) | Combination preparations comprising niacin and hmg-coa reductase inhibitor and the preparation method thereof | |
JPH09227371A (en) | Atherosclerosis inhibitor | |
US20070160663A1 (en) | Single unit pharmaceutical composition comprising a mixture of fenofibrate and a modified release form of a homocysteine reducing agent | |
RU2192856C1 (en) | Hypocholesterolemic agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 1200500065 Country of ref document: VN Ref document number: P-2005/0061 Country of ref document: YU |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2968/CHENP/2004 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005/00196 Country of ref document: ZA Ref document number: 200500196 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 537611 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 166279 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200702624 Country of ref document: VN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1-2005-500131 Country of ref document: PH Ref document number: CR2005-007658 Country of ref document: CR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2493076 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003261217 Country of ref document: AU Ref document number: 05004944 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: P20050081A Country of ref document: HR Ref document number: 375065 Country of ref document: PL Ref document number: PA/a/2005/001004 Country of ref document: MX Ref document number: 20038178443 Country of ref document: CN Ref document number: 2004524692 Country of ref document: JP Ref document number: 2003771709 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057001458 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 380.05 Country of ref document: BZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: DZP2005000030 Country of ref document: DZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 8662 Country of ref document: GE Ref document number: 200500279 Country of ref document: EA |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057001458 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003771709 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 380.05 Country of ref document: BZ |
|
WWP | Wipo information: published in national office |
Ref document number: 380.05 Country of ref document: BZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10523 Country of ref document: GE |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2008-009767 Country of ref document: CR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 191348 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12008501590 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: P20080518A Country of ref document: HR |